Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient understands study requirements and has given his/her written informed consent on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved consent form.~* Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain Bank Diagnostic criteria~* Minimum of 3 years since diagnosis.~* Meet Hoehn and Yahr PD stage~* Good response to levodopa~* Stable regimen of anti-PD medications~* Patients must have been taking a levodopa-containing anti-PD medication continuously for at least the previous 12 months~* Patient has documented a minimum amount of Off time.~* If of childbearing potential (male and female) must use an acceptable method of contraception~Exclusion Criteria:~* Previous tozadenant study participation~* Current or recent participation in another study.~* Secondary or atypical parkinsonism~* Neurosurgical intervention for PD~* Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®~* Treatment with excluded medications~* Untreated or uncontrolled hyperthyroidism or hypothyroidism~* Clinically significant out-of-range laboratory~* MMSE out of range~* Current episode of major depression (stable treatment for depression is permitted).~* Recent suicide attempt or suicidal ideation type 4 or type 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS)~* Women lactating or pregnant~* Hypersensitivity to any components of tozadenant or excipients~* Abnormal findings on the physical or neurological examination, or medical history that would make the patient unsuitable for the study~* History of hepatitis or cholangitis

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tozadenant 60 mg BID (Type: EXPERIMENTAL): During Part A, patients took two (2) tablets, one 60 mg tozadenant and one placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B.
- Tozadenant 120 mg BID (Type: EXPERIMENTAL): During Part A, patients took two (2) tablets of 60 mg tozadenant, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B.
- Placebo BID (Type: PLACEBO_COMPARATOR): During Part A, patients took two (2) tablets of placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B.

Based on this trial design, predict the completion outcome and termination type (if applicable).